Positron emission tomography computed tomography in oncology

British Journal of Hospital Medicine

Volumn 72, Issue 11, 2011, Pages 631-637

  Drake, Brent ^a   Cook, Gary J R ^b  

^a PLYMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80955166841     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2011.72.11.631     Document Type: Review

References (30)

1. Barrington SF, Qian WD, Somer EJ et al (2010) Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37: 1824-33
2. Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ (2011) Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol 12: 181-91
3. Boellaard R, O'Doherty MJ, Weber WA et al (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37: 181-200
4. Bryant AS, Cerfolio RJ (2006) The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 82: 1016-20
5. Buchs NC, Buhler L, Bucher P et al (2011) Value of contrastenhanced 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in detection and presurgical assessment of pancreatic cancer: A prospective study. J Gastroenterol Hepatol 26:657-62
6. Buijsen J, Van den Bogaard J, Janssen MHM et al (2011) FDGPET provides the best correlation with the tumor specimen compared to MRI and CT in rectal cancer. Radiother Oncol 98: 270-6
7. Bussink J, Kaanders J, Van der Graaf WTA, Oyen WJG (2011) PETCT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol 8: 233-42
8. Dong MJ, Zhao K, Lin XT, Zhao J, Ruan LX, Liu ZF (2008) Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a metaanalysis of the literature. Nucl Med Commun 29: 791-802
9. Evangelista L, Baretta Z, Vinante L et al (2011) Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer. Eur J Nucl Med Mol Imaging 38: 293-301
10. Fernandes AT, Shen J, Finlay J et al (2010) Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes. Radiother Oncol 95: 178-84
11. Fletcher JW, Djulbegovic B, Soares HP et al (2008a) Recommendations on the use of F-18-FDG PET in oncology. J Nucl Med 49: 480-508 (Pubitemid 351355215)
12. Fletcher JW, Kymes SM, Gould M et al (2008b) A comparison of the diagnostic accuracy of F-18-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med 49: 179-85 (Pubitemid 351225654)
13. Giovanella L, Suriano S, Maffioli M, Ceriani L (2011) 18FDGpositron emission tomography/computed tomography (PET/CT) scanning in thyroid nodules with nondiagnostic cytology. Clin Endocrinol 74: 644-8
14. Gold MA (2008) PET in cervical cancer-implications for 'staging,' treatment planning, assessment of prognosis, and prediction of response. J Natl Compr Canc Netw 6: 37-45 (Pubitemid 351212001)
15. Groves AM, Win T, Ben Haim S, Ell PJ (2007) Non- F-18 FDG PET in clinical oncology. Lancet Oncol 8: 822-30 (Pubitemid 47308671)
16. Heusner TA, Kuemmel S, Hahn S et al (2009) Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging 36: 1543-50
17. Hoilund-Carlsen PF, Gerke O, Vilstrup MH et al (2011) PET/CT without capacity limitations: a Danish experience from a European perspective. Eur Radiol 21: 1277-85
18. Isasi CR, Lu P, Blaufox MD (2005) A metaanalysis of F-18-2-deoxy-2- fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104: 1066-74 (Pubitemid 41170236)
19. Jadvar H, Alavi A, Gambhir SS (2009) F-18-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 50: 1820-7
20. Kwee TC, Basu S, Cheng G, Alavi A (2010) FDG PET/CT in carcinoma of unknown primary. Eur J Nucl Med Mol Imaging 37: 635-44
21. Lambrecht M, Haustermans K (2010) Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. Radiother Oncol 96: 339-46
22. Langer A (2010) A systematic review of PET and PET/CT in oncology: A way to personalize cancer treatment in a cost-effective manner? BMC Health Serv Res 10: 283
23. Lordick F, Ott K, Krause BDJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 8: 797-805 (Pubitemid 47308659)
24. Nannini M, Pantaleo MA, Maleddu A, AlL-Nahhas A, Rubello D, Fanti S, Biasco G (2009) The Response Evaluation Criteria in Solid Tumors: until when? Nucl Med Commun 30: 185-7
25. National Institute for Health and Clinical Excellence (2011) Lung Cancer (Update). http://guidance.nice.org.uk/CG/Wave17/23 (accessed 26 July 2011)
26. Paesmans M, Berghmans T, Dusart M et al; European Lung CANC Working Party, ILCSP (2010) Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer update of a systematic review and meta-Analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 5: 612-19
27. Papathanassiou D, Bruna-Muraille C, Liehn JC, Nguyen TD, Cure H (2009) Positron Emission Tomography in oncology: Present and future of PET and PET/CT. Crit Rev Oncol Hematol 72: 239-54
28. Segall G, Delbeke D, Stabin MG, Even-Sapir E, Fair J, Sajdak R, Smith GT (2010) SNM Practice Guideline for Sodium 18F-Fluoride PET/CT Bone Scans 1.0. J Nucl Med 51: 1813-20
29. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J (2010) The role of Ga-68-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on In-111-DTPA-Octreotide scintigraphy. J Nucl Med 51: 875-82
30. Xie P, Li MH, Zhao HX, Sun XD, Fu Z, Yu JM (2011) F-18-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. J Cancer Res Clin Oncol 137: 1085-93